Johnson & Johnson (JNJ) Enterprise Value (2009 - 2026)
Johnson & Johnson (JNJ) posted Enterprise Value of -$20.8 billion for Q2 2026, up 5.86% sequentially from -$22.1 billion in Q1 2026, and down 9.95% YoY from -$23.1 billion in Q2 2025.
Johnson & Johnson (JNJ) Enterprise Value (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Enterprise Value for 18 years, with the latest figure at -$20.8 billion in Q2 2026.
- Quarterly Enterprise Value fell 9.95% year-over-year to -$20.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$20.8 billion (down 9.95% YoY) and the FY2025 annual result came in at -$20.1 billion, up 18.02% from the prior year.
- Enterprise Value improved to -$20.8 billion in Q2 2026 per JNJ's latest filing, from -$22.1 billion in the prior quarter.
- Over five years, Enterprise Value peaked at -$18.6 billion in Q3 2025 and troughed at -$38.8 billion in Q1 2025.
- A 5-year average of -$25.5 billion and a median of -$24.5 billion in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2025 and 2026: Enterprise Value tumbled 47.92% in 2025, then soared 43.14% in 2026.
- Over 5 years, Enterprise Value stood at -$34.1 billion in 2022, then surged by 32.72% to -$22.9 billion in 2023, then declined by 6.96% to -$24.5 billion in 2024, then grew by 18.02% to -$20.1 billion in 2025, then declined by 3.26% to -$20.8 billion in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$20.8 billion, -$22.1 billion, and -$20.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -6.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -20.76 Bn |
| Mar 29, 2026 | -22.05 Bn |
| Dec 28, 2025 | -20.10 Bn |
| Sep 28, 2025 | -18.56 Bn |
| Jun 29, 2025 | -18.88 Bn |
| Mar 30, 2025 | -38.78 Bn |
| Dec 29, 2024 | -24.52 Bn |
| Sep 29, 2024 | -20.30 Bn |
| Jun 30, 2024 | -25.48 Bn |
| Mar 31, 2024 | -26.22 Bn |
| Dec 31, 2023 | -22.93 Bn |
| Oct 1, 2023 | -23.51 Bn |
| Jul 2, 2023 | -27.25 Bn |
| Apr 2, 2023 | -24.61 Bn |
| Jan 1, 2023 | -22.28 Bn |
| Oct 2, 2022 | -34.08 Bn |
| Jul 3, 2022 | -32.57 Bn |
| Apr 3, 2022 | -30.39 Bn |
| Jan 2, 2022 | -31.61 Bn |
| Oct 3, 2021 | -31.00 Bn |